Sartorius expands business in North America | state

ANN ARBOR , Me., September 27, 2021 / PRNewswire / – Sartorius, a leading international partner to life science research and the biopharmaceutical industry, is expanding its presence in Michigan. Sartorius will be in. Open a new, 12,000 square meter, state-of-the-art facility Ann Arbor End of 2023.

“The new location will continue the existing business operations in Washtenaw district to create a center of excellence in Ann Arbor for the laboratory and bioprocess products and services in North Americawho focus on delivering innovative solutions to help customers develop drugs that cure, prevent and stop disease, “said Mary Lavin, President of Sartorius North America.

Sartorius will have an anchor presence in the Tech Loop in the Ann Arbor Research Park and a flagship location in North America. To this end, the company has acquired over 15 hectares of land that offers enough space for further expansion. The project is expected to create 160 jobs in three years. These jobs include product development, operations, and other support functions.

The demand for innovative technologies for the development and production of biopharmaceuticals continues to grow rapidly. the Ann Arbor Location is an integral part of Sartorius’ ongoing global expansion, which enables Sartorius to expand its activities and capabilities in the Ann Arbor Biotech hub. Sartorius will more than double its capacities for its most important product groups by 2025.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied in such statements. Sartorius assumes no liability for updating such statements with regard to new information or future events.

A profile from Sartorius

The Sartorius Group is a leading international partner for life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Lab Products & Services division focuses on the needs of laboratories that carry out research and quality control in pharmaceutical and biopharmaceutical companies, as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio with a focus on single-use solutions, supports customers in the safe and efficient manufacture of biotechnological drugs and vaccines. The group has grown by an average of double digits each year and has regularly expanded its portfolio through acquisitions of complementary technologies. In the 2020 financial year, the company achieved sales of around EUR 2.34 billion. At the end of 2020, almost 11,000 people were employed for customers around the world at the Group’s around 60 production and sales locations.

Follow Sartorius on Twitter and LinkedIn.


Petra Kirchhoff

Head of Corporate Communications & Investor Relations

+49 (0) 551 308 1686

[email protected]

View original content:

SOURCE Sartorius AG

Comments are closed.